Hepatitis B Virus transcriptional activators: Mechanisms and possible role in oncogenesis

Journal of Viral Hepatitis

Volumn 3, Issue 3, 1996, Pages 109-121

  Henkler, F ^a   Koshy, R ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

Functional mechanisms; Hepatitis B virus; Hepatocellular carcinogenesis; Transactivation; X protein

Indexed keywords

HEPATITIS B VIRUS X PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR AP 1; VIRUS DNA;

ANIMAL; GENETICS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOGENICITY; PHYSIOLOGY; PROTO ONCOGENE; REGULATOR GENE; REVIEW; SCIURIDAE; SIGNAL TRANSDUCTION; TRANSACTIVATION; VIROLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; DNA, VIRAL; GENES, REGULATOR; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MARMOTA; NF-KAPPA B; PROTO-ONCOGENES; SCIURIDAE; SIGNAL TRANSDUCTION; TRANS-ACTIVATION (GENETICS); TRANS-ACTIVATORS; TRANSCRIPTION FACTOR AP-1;

EID: 0030133133     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.1996.tb00001.x     Document Type: Review

References (130)

1. Koshy R, Meyer M. Oncogenicity of hepatitis B virus. Rev Med Virol 1992; 2: 131-140.
2. Hadziyannis SJ. Chronic viral hepatitis. Clin Gastroenterol 1974; 3(2): 391-408.
3. Hadziyannis SJ. Hepatocellular carcinoma and type B hepatitis. Clin Gastroenterol 1980; 9(1): 117-134.
4. Beasley RP. Hepatitis B virus as the ethiologic agent in hepatocellular carcinoma epidemiologic considerations. Hepatology 1982; 2: 21S-26S.
5. Beasley RP, Linn CC, Hwang LY, Chen CS. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22.707 men in Taiwan. Lancet 1981; 2: 1129-1133.
6. Ganem D, Varmus HE. The molecular biology of the hepatitis B viruses. Annu Rev Biochem 1987; 56: 651-693.
7. Summers J, Mason WS. Replication of the genome of a hepatitis B-like virus by reverse transcription of an RNA intermediate. Cell 1982; 29(2): 403-415.
8. Seeger C, Summers J, Mason WS. Viral DNA synthesis. Curr Top Microbiol Immunol 1991; 168: 41-60.
9. Zuckerman AJ, Thomas HC, eds. Viral Hepatitis. Edinburgh: Churchill Livingstone, 1993.
10. Hertogs K, Leenders WP, Depla E et al. Endonexin II, present on human liver plasma membranes, is a specific binding protein of small hepatitis B virus (HBV) envelope protein. Virology 1993; 197(2): 549-557.
11. Treichel U, Meyer zum Buschenfelde KH, Stockert RJ, Poralla T, Gerken G. The asialoglycoprotein receptor mediates hepatic binding and uptake of natural hepatitis B virus particles derived from viraemic carriers. J Gen Virol 1994; 75(11): 3021-3029.
12. Nassal M, Schaller H. Hepatitis B virus replication. Trends Microbiol 1993; 1(6): 221-228.
13. Valenzuela P, Quiroga M, Zaldivar J, Gray P, Rutter WJ. The nucleotide sequence of the hepatitis B viral genome and identification of major viral genes. In: Fields BN, Jaenisch R, Fox CF, eds. Animal Virus Genetics. New York: Academic Press, 1980: pp 57-70.
14. Galibert F, Mandart E, Fitoussi F, Tiollais P, Charnay P. Nucleotide sequence of the hepatitis B virus genome (subtype ayw) cloned in E. coli. Nature 1979; 281(5733): 646-650.
15. Delius H, Gough NM, Cameron CH, Murray K. Structure of the hepatitis B virus genome. J Virol 1983; 47(2): 337-343.
16. Pasek M, Goto T, Gilbert W et al. Hepatitis B virus genes and their expression in E. coli. Nature 1979; 282(5739): 575-579.
17. Toh H, Hayashida H, Miyata T. Sequence homology between retroviral reverse transcriptase and putative polymerases of hepatitis B virus and cauliflower mosaic virus. Nature 1983; 305(5937): 827-829.
18. Radziwill G, Tucker W, Schaller H. Mutational analysis of the hepatitis B virus P gene product: domain structure and RNase H activity. J Virol 1990; 64(2): 613-620.
19. Weber M, Bronsema V, Bartos H, Bosserhoff A, Bartenschlager R, Schaller H. Hepadnavirus P protein utilizes a tyrosine residue in the TP domain to prime reverse transcription. J Virol 1994; 68(5): 2294-2299.
20. Miller RH, Robinson WS. Common evolutionary origin of hepatitis B virus and retroviruses. Proc Natl Acad Sci USA 1986; 83(8): 2531-2535.
21. Spandau DF, Lee-CH. Trans-activation of viral enhancers by the hepatitis B virus X protein. J Virol 1988; 62(2): 427-434.
22. Zahm P, Hofschneider PH, Koshy R. The HBV X-ORF encodes a transactivator: a potential factor in viral hepatocarcinogenesis. Oncogene 1988; 3(2): 169-177.
23. Seto E, Yen TS, Peterlin BM, Ou JH. Trans-activation of the human immunodeficiency virus long terminal repeat by the hepatitis B virus X protein. Proc Natl Acad Sci USA 1988; 85(21): 8286-8290.
24. Twu JS, Schloemer RH. Transcriptional trans-activating function of hepatitis B virus. J Virol 1987; 61(11): 3448-3453.
25. Rossner MT. Review: hepatitis B virus X-gene product: a promiscuous transcriptional activator. J Med Virol 1992; 36(2): 101-117.
26. Twu JS, Lai MY, Chen DS, Robinson WS. Activation of protooncogene c-jun by the X protein of hepatitis B virus. Virology 1993; 192(1): 346-350.
27. Avantaggiati ML, Natoli G, Balsano C et al. The hepatitis B virus (HBV) pX transactivates the c-fos promoter through multiple cis-acting elements. Oncogene 1993; 8(6): 1567-1574.
28. Menzo S, Clementi M, Alfani E et al. Trans-activation of epidermal growth factor receptor gene by the hepatitis B virus X-gene product. Virology 1993; 196(2): 878-882.
29. Zhou DX, Taraboulos A, Ou JH, Yen TS. Activation of class I major histocompatibility complex gene expression by hepatitis B virus. J Virol 64(8): 4025-4028.
30. Hu KQ, Yu CH, Vierling JM. Up-regulation of intercellular adhesion molecule 1 transcription by hepatitis B virus X protein. Proc Natl Acad Sci USA 1992; 89(23): 11441-11445.
31. Kay A, Mandart E, Trépo C, Galibert F. The HBV HBx gene expressed in E. coli is recognised by sera from hepatitis patients. EMBO J 1985; 4: 1287-1292.
32. Moriarty AM, Alexander H, Lerner RA. Antibodies to peptides detect new hepatitis B antigen: serological correlation with hepatocellular carcinoma. Science 1985; 227: 429-433.
33. Elfassi E, Haseline WA, Dienstag JL. Detection of hepatitis B virus X product using an open reading frame Escherichia coli expression vector. Proc Natl Acad Sci USA 1986; 83: 2219-2222.
34. Meyers ML, Vitvitski-Trépo LV, Nath N, Sninsky JJ. Hepatitis B virus polypeptide X: expression in Escherichia coli and identification of specific antibodies in sera from hepatitis B virus-infected humans. J Virol 1986; 57: 101-109.
35. Pfaff E, Salfeld J, Gmelin K, Schaller H, Theilmann L. Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera. Virology 1987; 158: 456-460.
36. Hess J, Stemler M, Will H, Schröder CH, Kuhn J, Braun R. Frequent detection of antibodies to hepatitis B virus x-protein in acute, chronic and resolved infections. Med Microbiol Immunol 1988; 177: 195-205.
37. Katayama K, Hayashi N, Sasaki Y et al. Detection of hepatitis B virus X gene protein and antibody in type B chronic liver disease, 1989. Gastroenterology 1989; 97: 990-998.
38. Vitvitski-Trépo L, Kay A, Pichoud C et al. Early and frequent detection of HBxAg and/or anti-HBx in hepatitis B virus infection. Hepatology 1990; 12: 1278-1283.
39. Haruna Y, Hayashi N, Katayama K et al. Expression of the X protein and hepatitis B replication in chronic hepatitis. Hepatology 1991; 13: 417-421.
40. Wang WL, London WT, Lega L, Feitelson MA. HBxAg in the liver from carrier patients with chronic hepatitis and cirrhosis. Hepatology 1991; 14(1): 29-37.
41. Zentgraf H, Herrmann G, Klein R et al. Mouse monoclonal antibody directed against hepatitis B virus X protein synthesized in Escherichia coli: detection of reactive antigen in liver cell carcinoma and chronic hepatitis. Oncology 1990; 47(2): 143-148.
42. Henkler F, Waseem N, Golding M, Alison M, Koshy R. Mutant p53, but not hepatitis B virus X protein is present in hepatitis B virus related human hepatocellular carcinoma. Cancer Res 1995; 55: 6084-6091.
43. Nakatake H, Chisaka O, Yamamoto S, Matsubara K, Koshy R. Effect of X protein on transactivation of hepatitis B virus promoters and on viral replication. Virology 1993; 195(2): 305-314.
44. Yaginuma K, Shirakata Y, Kobayashi M, Koike K. Hepatitis B virus (HBV) particles are produced in a cell culture system by transient expression of transfected HBV DNA. Proc Natl Acad Sci USA 1987; 84(9): 2678-2682.
45. Blum HE, Zhang ZS, Galun E, von Weizsäcker F, Garner B, Liang TJ, Wands JR. Hepatitis B virus X protein is not central to the viral life cycle in vitro. J Virol 1992; 66(2): 1223-1227.
46. Chen HS, Kaneko S, Grones R et al. The woodchuck hepatitis virus X gene is important for establishment of virus infection in woodchucks. J Virol 1993; 67: 1218-1226.
47. Zoulim F, Saputelli J, Seeger C. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol 1994; 68(3): 2026-2030.
48. Kwee L, Lucito R, Aufiero B, Schneider RJ. Alternate translation initiation on hepatitis B virus X-mRNA produces multiple polypeptides that differentially transactivate class II and III promoters. J Virol 1992; 66(7): 4382-4389.
49. Mandart E, Kay A, Galibert F. Nucleotide sequence of a cloned duck hepatitis B virus genome: comparison with woodchuck and human hepatitis B virus sequences. J Virol 1994; 49(3) 782-792.
50. Balsano C, Billet O, Bennoun M et al. Hepatitis B virus X gene product acts as a transactivator in vivo. J Hepatol 1994; 21(1): 103-109.
51. Twu JS, Chu K, Robinson WS. Hepatitis B virus X gene activates kappa B-like enhancer sequences in the long terminal repeat of human immunodeficiency virus 1. Proc Natl Acad Sci USA 1989; 86(13): 5168-5172.
52. Seto E, Mitchell PJ, Yen TS. Transactivation by the hepatitis B virus X protein depends on AP-2 and other transcription factors. Nature 1990; 344(6261): 72-74.
53. Maguire HF, Hoeffler JP, Siddiqui A. HBV X protein alters the DNA binding specificity of CREB and ATF-2 by protein-protein interactions. Science 1991; 252(5007): 842-844.
54. Williams JS, Andrisani OM. The hepatitis B virus X protein targets the basic region-leucine zipper domian of CREB. Proc Natl Acad Sci USA 1995; 92(9): 3819-3823.
55. Autunovic J, Lemieux N, Cromlish JA. The 17 kDa HBx protein encoded by hepatitis B virus interacts with the activation domains of Oct-1, and functions as a coactivator in the activation and repression of a human U6 promoter. Cell Mol Biol Res 1993; 39(5): 463-482.
56. Unger T, Shaul Y. The X protein of the hepatitis B virus acta as a transcription factor when targeted to its responsive element. EMBO J 1990; 9(6): 1889-1895.
57. Qadri I, Maguire HF, Siddiqui A. Hepatitis B virus transactivator protein X interacts with the TATA-binding protein. Proc Natl Acad Sci USA 1995; 92(4): 1003-1007.
58. Cheong JH, Yi M, Lin Y, Murakami S. Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation. EMBO J 1995; 14(1): 142-150.
59. Kashanchi F, Piras G, Radonovich MF et al. Direct interaction of human TFIID with the HIV-1 transactivator tat. Nature 1994; 367(6460): 295-299.
60. Caron C, Rousset R, Beraud C, Moncollin V, Egly JM, Jalinot P. Functional and biochemical interaction of the HTLV-I Tax1 transactivator with TBP. EMBO J 1993; 12(11): 4269-4278.
61. Moran E. Mammalian cell growth controls reflected through protein interactions with the adenovirus E1A gene products. Semin Virol 1994; 5: 327-340.
62. Stringer KF, Ingles CJ, Greenblatt J. Direct and selective binding of an acidic transcriptional activation domain to the TATA-box factor TFIID. Nature 1990; 345(6278): 783-786.
63. Nevins JR. Transcriptional activation by viral regulatory proteins. Trends Biochem Sci 1991; 16(11): 435-439.
64. Kekulé AS, Lauer U, Weiss L, Luber B, Hofschneider PH. Hepatitis B virus transactivator HBx uses a tumour promoter signalling pathway. Nature 1993; 361(6414): 742-745.
65. Kekulé AS, Lauer U, Weiss L, Hofschneider PH, Koshy R. Trans-activation by hepatitis B virus X protein is mediated via a tumour promoter pathway. Arch Virol (Suppl) 1992; 4: 63-64.
66. Cross JC, Wen P, Rutter WJ. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen-activated cellular serine/threonine kinases. Proc Natl Acad Sci USA 1993; 90(17): 8078-8082.
67. Natoli G, Avantaggiati ML, Chirillo P et al. Induction of the DNA-binding activity of c-jun/c-fos heterodimers by the hepatitis B virus transactivator pX. Mol Cell Biol 1994; 14(2): 989-998.
68. Lucito R, Schneider RJ. Hepatitis B virus X protein activates transcription factor NF-kappa B without a requirement for protein kinase C. J Virol 1992; 66(2): 983-991.
69. Meyer M, Caselmann WH, Schlüter V, Schreck R, Hofschneider PH, Baeuerle PA. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 1992; 11(8): 2991-3001.
70. Benn J, Schneider RJ. Hepatitis B virus HBx protein activates Ras-GTP complex formation and establishes a Ras, Raf, MAP kinase signaling cascade. Proc Natl Acad Sci USA 1994; 91: 10350-10353.
71. Natoli G, Avantaggiati ML, Chirillo P et al. Ras- and Raf-dependent activation of c-jun transcriptional activity by the hepatitis B virus transactivator pX. Oncogene 1994; 9(10): 2837-2843;
72. EMBO J 1994; 9: 1137-1145.
73. Chisaka O, Araki K, Ochiya T et al. Purification of hepatitis B virus gene X product synthesized in Escherichia coli and its detection in a human hepatoblastoma cell line producing hepatitis B virus. Gene 1987; 60(2-3): 183-189.
74. Siddiqui A, Jameel S, Mapoles J. Expression of the hepatitis B virus X gene in mammalian cells. Proc Natl Acad Sci USA 1987; 84(8): 2513-2517.
75. Schek N, Bartenschläger R, Kuhn C, Schaller H. Phosphorylation and rapid turnover of hepatitis B virus X-protein expressed in HepG2 cells from a recombinant vaccini virus. Oncogene 1991; 6(10): 1735-1744.
76. Renner M, Haniel A, Bürgelt E, Hofschneider HP, Koch W. Transactivating function and expression of the X gene of hepatitis B virus. J Hepatol 1995; 23: 43-65.
77. Höhne M, Schaefer S, Seifer M, Feitelson MA, Paul D, Gerlich WH. Malignant transformation of immortalized transgenic hepatocytes after transfection with hepatitis B virus DNA. EMBO J 1990; 9(4): 1137-1145.
78. Doria M, Klein N, Lucito R, Schneider RJ. The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J 1995; 14: 4747-4757.
79. Sontag E, Fedorov S, Kamibayashi C, Robbins D, Cobb M, Mumby M. The interaction of SV40 small tumor antigen with protein phosphatase 2A stimulates the map kinase pathway and induces cell proliferation. Cell 1993; 75(5): 887-897.
80. Petti L, Nilson LA, DiMaio D. Activation of the platelet-derived growth factor receptor by the bovine papillomavirus E5 transforming protein. EMBO J 1991; 10(4): 845-855.
81. Dilworth SM, Brewster CE, Jones MD, Lanfrancone L, Pelicci G, Pelicci PG. Transformation by polyoma virus middle T-antigen involves the binding and tyrosine phosphorylation of Shc. Nature 1994; 367(6458): 87-90.
82. Takada S, Koike K. The X protein of hepatitis B virus resembles a serine protease inhibitor. Jap J Cancer Res 1990; 81: 1191-1194.
83. de-Medina T, Haviv I, Noiman, S, Shaul Y. The X protein of hepatitis B virus has a ribo/deoxy ATPase activity. Virology 1994; 202(1): 401-407.
84. Timmers HT, Meyers RE, Sharp PA. Composition of transcription factor B-TFIID. Proc Natl Acad Sci USA 1992; 89(17): 8140-8144.
85. Feitelson MA, Zhu M, Duan LX, London WT. Hepatitis B x antigen and p53 leads to inhibition of HBx of p53 are associated in vitro and in liver tissues from patients with primary hepatocellular carcinoma. Oncogene 1993; 8(5): 1109-1117.
86. Wang XW, Forrester K, Yeh H, Feitelson MA, Gu JR, Harris CC. Hepatitis B virus X protein inhibits sequence-specific DNA binding, transcriptional activity and association with transcription factor ERCC3. Proc Natl Acad Sci USA 1994; 91: 2230-2234.
87. Truant R, Antunovic J, Greenblatt J, Prives C, Cromlish JA. Direct interaction of the hepatitis B virus HBx protein with p53 response element-directed transactivation. J Virol 1995; 69: 1851-1859.
88. Rao L, Debbas M, Sabbatini P, Hockenbery D, Korsmeyer S, White E. The adenovirus E1A proteins induce apoptosis, which is inhibited by the E1B 19-kDa and Bcl-2 proteins. Proc Natl Acad Sci USA 1992; 89: 7742-7746.
89. White E. Function of the adenovirus E1B oncogene in infected and transformed cells. Semin Virol 1994; 5: 341-348.
90. Concen SD, Cole CN. The transforming proteins of simian virus 40. Semin Virol 1994; 5: 349-356.
91. Huibretse JM, Scheffner M. Mechanisms of tumor suppressor protein inactivation by the human papillomavirus E6 and E7 oncoproteins. Semin Virol 5: 357-367.
92. Fourel G, Trépo C, Bougueleret L et al. Frequent activation of N-myc genes by hepadnavirus insertion in woodchuck liver tumours. Nature 1990; 347(6290): 294-298.
93. Tokino T, Matsubara K. Chromosomal sites for hepatitis B virus integration in human hepatocellular carcinoma. J Virol 1991; 65(12): 6761-6764.
94. de Thé H, Marchio A, Tiollais P, Dejean A. A novel steroid thyroid homrone receptor-related gene inappropriately expressed in human hepatocellular carcinoma. Nature 1987; 330(6149): 667-670.
95. Wang J, Chenivesse X, Henglein B, Bréchot C. Hepatitis B virus integration in a cyclin A gene in a hepatocellular carcinoma. Nature 1990; 343(6258): 555-557.
96. Zhang XK, Egan JO, Huang D, Sun ZL, Chien VK, Chiu JF. Hepatitis B virus DNA integration and expression of an erb B-like gene in human hepatocellular carcinoma. Biochem Biophys Res Commun 1992; 188(1): 344-351.
97. Graef E, Caselmann WH, Wells J, Koshy R. Insertional activation of mevalonate kinase by hepatitis B virus DNA in a human hepatoma cell line. Oncogene 1994; 9(1): 81-87.
98. Zhou YZ, Butel JS, Li-PJ, Finegold MJ, Melnick JL. Integrated state of subgenomic fragments of hepatitis B virus DNA in hepatocellular carcinoma from mainland China. J Natl Cancer Inst 1987; 79(2): 223-231.
99. Wollersheim M, Debelka U, Hofschneider PH. A trans-activating function encoded in the hepatitis B virus X gene is conserved in the integrated state. Oncogene 1988; 3(5) 545-552.
100. Takada S, Koike K. Trans-activation function of a 3′ truncated X gene-cell fusion product from integrated hepatitis B virus DNA in chronic hepatitis tissues. Proc Natl Acad Sci USA 1990; 87(15): 5628-5632.
101. Schlüter V, Meyer M, Hofschneider PH, Koshy R, Caselmann WH. Integrated hepatitis B virus X and 3′ truncated preS/S sequences derived from human hepatomas endode functionally active transactivators. Oncogene 1994; 9(11): 3335-3344.
102. Hilger C, Velhagen I, Zentgraf H, Schröder CH. Diversity of hepatitis B virus X gene related transcripts in hepatocellular carcinoma: a novel polyadenylation site on viral DNA. J Virol 1991; 65: 4284-4291.
103. Paterlini P, Poussin K, Kew M, Franco D, Bréchot C. Selective accumulation of the X transcript of hepatitis B virus in patients negative for hepatitis B surface antigen with hepatocellular carcinoma. Hepatology 1995; 21(2) 313-321.
104. Wei U, Etiemble J, Fourel G, Vitvitski-Trépo L, Buendia MA. Hepadna virus integration generates virus-cell cotranscripts carrying 3′ truncated X genes in human and woodchuck liver tumors. J Med Virol 1995; 45(1): 82-90.
105. Wang WL, London WT, Feitelson MA. Hepatitis Bx antigen in hepatitis B virus carrier patients with liver cancer. Cancer Res 1991; 51(18): 4971-4977.
106. Seifer M, Höhne M, Schaefer S, Gerlich WH. In vitro tumorigenicity of hepatitis B virus DNA and HBx protein. J Hepatol 1991; 13(Suppl 4): S61-S65.
107. Seifer M, Gerlich WH. Increased growth of permanent mouse fibroblasts in soft agar after transfection with hepatitis B virus DNA. Arch Virol 126(1-4): 119-128.
108. Kim CM, Koike K, Saito I, Miyamura T, Jay G. HBx gene of hepatitis B virus induces liver cancer in transgenic mice. Nature 1991; 351(6324): 317-320.
109. Lee TH, Finegold MJ, Shen RF, DeMayo JL, Woo SL, Butel JS. Hepatitis B virus transactivator X protein is not tumorigenic in transgenic mice. J Virol 1990; 64(12): 5939-5947.
110. Balsano C, Avantaggiati ML, Natoli G et al. Full-length and truncated versions of the hepatitis B virus (HBV) X protein (pX) transactivate the c-myc protooncogene at the transcriptional level. Biochem Biophys Res Commun 1991; 176(3): 985-992.
111. Koike K, Shirakata Y, Yaginuma K et al. Oncogenic potential of hepatitis B virus. Mol Biol Med 1989; 6(2): 151-160.
112. Shirakata Y, Kawada M, Fujiki Y et al. The X gene of hepatitis B virus induced growth stimulation and tumorigenic transformation of mouse NIH3T3 cells. Jap J Cancer Res 1989; 80(7): 617-621.
113. Desmet VJ. Immunopathology of chronic viral hepatitis. Hepatogastroenterology 1991; 38(1): 14-21.
114. Hu KQ, Vierling JM, Siddiqui A. Trans-activation of HLA-DR gene by hepatitis B virus X gene product. Proc Natl Acad Sci USA 1990; 87(18): 7140-7144.
115. Gonzalez Amaro R, Garcia Monzon C, Garcia Buey L et al. Induction of tumor necrosis factor alpha production by human hepatocytes in chornic viral hepatitis. J Exp Med 1994; 1790: 841-848.
116. Ueda J, Ullrich SJ, Gangemi JD et al. Functional inactivaton but not structural mutation of p53 causes liver cancer. Nature Genet 1995; 9(1): 41-47.
117. Hsu IC, Metcalf RA, Sun T, Welsh JA, Wang NJ, Harris CC. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428.
118. Ozturk M et al. p53 mutation in hepatocellular carcinoma after aflatoxin exposure. Lancet 1991; 338(8779): 1356-1359.
119. Goldblum JR, Bartos RE, Carr KA, Frank TS. Hepatitis B and alterations of the p53 tumor suppressor gene in hepatocellular carcinoma. Am J Surg Pathol 1993; 17(12): 1244-1251.
120. Volkmann M, Hofmann WJ, Müller M et al. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene 1994; 9: 195-204.
121. Aguilar F, Hussain SP, Cerutti P. Aflatoxin B1 induces the transversion of G→T in codon 249 of the p53 tumor suppressor gene in human hepatocytes. Proc Natl Acad Sci USA 1993; 90(18): 8586-8590.
122. Kekule AS, Lauer U, Meyer M, Caselmann WH, Hofschneider PH, Koshy R. The preS2/S region of integrated hepatitis B virus DNA encodes a transcriptional transactivator. Nature 1990; 343(6257): 457-461.
123. Caselmann WH, Meyer M, Kekule AS, Lauer U, Hofschneider PH, Koshy R. A trans-activator function is generated by integration of hepatitis B virus preS/S sequences in human hepatocellular carcinoma DNA. Proc Natl Acad Sci USA 1990; 87(8): 2970-2974.
124. Natoli G, Balsano C, Avantaggiati ML et al. Truncated pre-S/S proteins transactivate multiple target sequences. Arch Virol (Suppl) 1992; 4: 65-69.
125. Lauer U, Weiss L, Hofschneider PH, Kekule AS. The hepatitis B virus pre-S/S(t) transactivtor is generated by 3′ truncations within a defined region of the S gene. J Virol 1992; 66(9): 5284-5289.
126. Hildt E, Urban S, Lauer U, Hofschneider PH, Kekule AS. ER-localization and functional expression of the HBV transactivator MHBst. Oncogene 8(12): 3359-3367.
127. Natoli G, Avantaggiati ML, Balsano C et al. Characterization of the hepatitis B virus preS/S region encoded transcriptional transactivator. Virology 1992; 187(2): 663-670.
128. Meyer M, Caselmann WH, Schlüter V, Schreck R, Hofschneider PH, Baeuerle PA. Hepatitis B virus transactivator MHBst: activation of NF-kappa B, selective inhibition by antioxidants and integral membrane localization. EMBO J 11(8): 2991-3001.
129. Lauer U, Weiss L, Lipp M, Hofschneider PH, Kekule AS. The hepatitis B virus preS2/St transactivator utilizes Ap-1 and other transcription factors for transactivation. Hepatology 1994; 19(1): 23-31.
130. Caselmann WH. Transactivation of cellular gene expression by hepatitis B viral proteins: a possible molecular mechanism of hepatocarcinogenesis. J Hepatol 1995; 22 (Suppl): 34-37.